Portfolio

Open Innovation Platform and Portfolio

60° Pharmaceuticals, LLC (60P) has embraced an open innovation platform to generate intellectual property and build our portfolio. We have or are collaborating with leading research institutions in the United States, Australia, Singapore and Italy to discover and develop oral medications for dengue fever. We are currently planning a clinical development campaign for two drug candidates, a platelet activating factor receptor antagonist (60P002), and an alpha glucosidase I inhibitor (60P001), and are continuing to seek new in-licensing opportunities.

Portfolio

Website Builder